Search Results for: Global Cancer Vaccine Market to
Articles
Technology Advancements in Protein Therapeutics Spurring Market Growth to $248.7 Billion May 31, 2016
Protein drugs have gained importance for their therapeutic applications, and the numbers of products have increased in recent years. BCC...CEL-SCI Reports Record Monthly Patient Enrollment for Phase III Head & Neck Cancer Trial May 9, 2016
CEL-SCI Corporation recently announced that during the month of April, it has enrolled 41 patients in its ongoing Phase III...Inovio Partners With National Cancer Institute & Mayo Clinic to Initiate Hepatitis C Immunotherapy Clinical Trial May 2, 2016
Inovio Pharmaceuticals, Inc. recently announced its immunotherapy for hepatitis C (INO-8000) will be evaluated in a Phase I trial in...CELL CULTURE MARKET - 3D Cell Cultures: Next Generation & New Challenges November 19, 2015
Kevin James and Robert G. Hunter of BCC Research say significant growth within the biopharmaceuticals industry is spurring unprecedented innovation in and demand for cell culture products for the purposes of drug discovery and safety testing. While 2D cell cultures have been in laboratory use since the 1950s, the market for 3D cultures has witnessed spectacular growth throughout the past decade.
Cristal Therapeutics & PX Biosolutions to Develop Innovative Vaccines July 16, 2015
Cristal Therapeutics, a privately-held life sciences company developing innovative products against cancer and other diseases, by using its patented nanotechnology...Vaxon Biotech Granted Patent for New Cancer Vaccine Candidates June 29, 2015
Vaxon Biotech recently announced it has been granted a new patent in Japan. This patent (JP application n°2012-502822) covers a...PDC*line Pharma Receives Advanced-Therapy Medicinal Product Classification for New Class of Therapeutic Cancer Vaccines June 18, 2015
PDC*line Pharma recently announced that PDC*vac, its new class of therapeutic cancer vaccines based on a line of Plasmacytoid Dendritic...Targeted Lung Cancer Therapies Are Supplanting Conventional Treatments March 3, 2015
Although lung cancer is the third most prevalent cancer type in the world, there are only 18 drugs in the...DNA VACCINES MARKET - DNA Vaccines: Strategic Markets & Emerging Technologies November 17, 2014
Kevin James, Shalini Dewan, MS, and Jon Evans, MBA, say the global market for DNA vaccines is estimated at $305.3 million for 2014 and is forecast to grow at a stellar 54.8% compound annual growth rate (CAGR) to reach $2.7 billion by 2019.
Cancer Research Technology Introduces Ximbio October 24, 2014
Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK, recently announced the launch of Ximbio (www.ximb.io),...Latest Frost Reports: Next-Generation Therapeutics for Infectious Diseases; Orphan Drugs Market March 31, 2014
Next-Generation Therapeutics The available antivirals for commonly occurring infections, such as respiratory syncytial virus (RSV) and influenza are characterized by...Rapid Delivery Program Product Portfolio Expands to Biopharmaceutical Injectable Market November 26, 2013
BD Medical recently announced the BD Accelerate program now offers a solution for the biopharmaceutical injectable drug market with the...THERAPEUTIC FOCUS - New Therapeutics for Aggressive Brain Cancers October 3, 2013
Jeffrey Bacha, MBA, says glioblastoma is one of the most common and fatal brain cancers, and new therapies to treat this disease are urgently needed. New approaches, such as vaccines and immunotherapies, have promising results, and to be most effective, will need to be used in combination with a chemotherapeutic.
BioAlliance Pharma Signs Collaborative Agreement With Vaccine Leader February 28, 2013
BioAlliance Pharma SA recently announced a collaboration agreement with one of the world-leading vaccine companies to develop a vaccine...Nexavar Continues to Dominate Advanced Liver Cancer Therapy February 17, 2013
Hepatocellular carcinoma (HCC), the most common form of liver cancer, carries a deadly reputation, and patients face shrinking hopes...Novavax Reports Significant Vaccine Development Progress January 4, 2012
Novavax, Inc. recently announced that CPL Biologics (CPLB), its joint venture in India with Cadila Pharmaceuticals Ltd., has made significant...Activartis Develops Cancer Vaccine in Phase II, Seeks Partner October 27, 2011
Activartis GmbH (formerly Trimed Biotech GmbH) recently announced it is developing a cancer immunotherapy concept that is currently in Phase...Kincell Bio & Imugene Announce Strategic Manufacturing & Process Development Partnership April 16, 2024
Kincell Bio to acquire Imugene’s North Carolina manufacturing facility for up to $6M USD in upfront and milestone-driven payments over 3 years….
DRUG DEVELOPMENT EXECUTIVE - Thermo Fisher Scientific: What to Expect From the Next Wave of RNA-Based Therapeutics February 29, 2024
Dr. Dale Patterson, Vice President and General Manager, Molecular Biology at Thermo Fisher Scientific, delves into the world of RNA therapies and understand their next act beyond COVID-19.
CLINICAL TRIALS - The Power of AI in Overcoming Patient Diversity Challenges January 26, 2024
Isaac Bentwich, PhD, explores why patient diversity is such a challenge for clinical trials, where that pain is often felt the most, some of the regulatory, technological, and industry changes already underway to solve the clinical trial gap, and where AI changes the future of patient diversity.
